“Together, we need to create a framework for equity-based tiered pricing to ensure that the price of innovative medicines can vary between countries, depending on their economic level and ability to pay.” Says Lars Fruergaard Jørgensen, Novo Nordisk president and CEO, and EFPIA vice-president to The Economist.
There are significant differences in patients’ access to medicines across Europe. How quickly a patient can benefit from a new treatment is more likely to be based on where they live, rather than on what they need. Faster, more equitable access to medicines across Europe has become a key priority for the research-based pharma industry and policymakers alike. Read more
An interview with Álmath Spooner, Vice-Chair of EFPIA IEGU WG and an Observer to DARWIN EU Advisory Board.
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.